Cargando…
Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review
BACKGROUND: The introduction of cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with either oxaliplatin or mitomycin C for patients with colorectal peritoneal metastasis (CPM) has resulted in a major increase in overall survival. Nonetheless, despite critica...
Autores principales: | Hulshof, Emma C., Lim, Lifani, de Hingh, Ignace H. J. T., Gelderblom, Hans, Guchelaar, Henk-Jan, Deenen, Maarten J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575928/ https://www.ncbi.nlm.nih.gov/pubmed/33117169 http://dx.doi.org/10.3389/fphar.2020.577968 |
Ejemplares similares
-
Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies
por: Guchelaar, Niels A. D., et al.
Publicado: (2023) -
mPEG-PDLLA Micelles Potentiate Docetaxel for Intraperitoneal Chemotherapy in Ovarian Cancer Peritoneal Metastasis
por: Zhang, Yumei, et al.
Publicado: (2022) -
Hyperthermic Intraperitoneal Chemotherapy: A Critical Review
por: Ceelen, Wim, et al.
Publicado: (2021) -
Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial
por: de Boer, Nadine Leonie, et al.
Publicado: (2019) -
Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis
por: Lin, En-Kwang, et al.
Publicado: (2016)